# Emerging Infections Program

Source: https://welltoldgrants.com/grants/cdc-rfa-ck24-2401-emerging-infections-program/  
Official notice: https://www.grants.gov/search-results-detail/345775

> Centers for Disease Control - NCEZID offered grants to any type of organization. It expected to make about 15 awards worth $767 million in total. Applications closed on June 20, 2023.

| Field | Value |
|---|---|
| Opportunity number | CDC-RFA-CK24-2401 |
| Agency | Centers for Disease Control - NCEZID |
| Status | Forecast |
| Deadline | June 20, 2023 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 15 |
| Total funding | $767 million |
| Cost sharing | not required |
| Assistance Listings | 93.317 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

The eligibility criteria below will be used to determine whether the applicant has met the program responsiveness criteria for Phase I Review. AuthorityEligible applicants must have the public health authority, legislative mandate or otherwise show legal access to the requisite data to conduct population-based infectious disease surveillance and take appropriate public health action based on the data. This authority allows unique and specific access to individual-level identifiable data from multiple data sources that are required to implement the activities outlined in this NOFO and in the individual EIP Programmatic “Approach” sections in Attachment 1 – EIP 2024 Activities. Eligible applicants must document this authority in "Other Attachment Forms" with attachment name "Legal Authority". CDC will consider any application that does not include this required documentation as non-responsive, and it will receive no further review. For eligible applicants who do not explicitly possess the public health authority or legislative mandate but are able to receive access to data (with a commitment and pathway to taking public health action) from their respective public health agency, these applicants must submit a signed letter from public health agency leadership or designee on organizational letterhead. This data access must allow for unique and specific access to individual-level identifiable data from multiple data sources that are required to implement the activities outlined in this NOFO and in the individual EIP Programmatic “Approach” sections in Attachment 1 – EIP 2024 Activities. In order to be responsive to the Phase I Review, the signed letter by the public health agency leadership or designee must also include the role(s) of the public health agency (e.g., co-lead and participate in which EIP activities throughout the five-year period of performance, etc.) and explicitly state that they agree to provide the applicant access to public health data needed for the proposed EIP activities for the catchment population of [enter catchment population for your jurisdiction] in [enter your jurisdiction] for the duration of the period of performance. Eligible applicants must document this data access in "Other Attachment Forms" with attachment name "Data Access". CDC will consider any application that does not include this required documentation as non-responsive, and it will receive no further review.

## What the grant funds

The Emerging Infections Program (EIP) was initiated in 1995 in response to the growing concern over the emergence and re-emergence of infectious diseases. Following the 1992 Institute of Medicine report "Emerging Infections: Microbial Threats to the United States,” CDC developed and published in 1994 a plan for addressing these threats. That plan highlighted the foundational role of public health surveillance and included in its recommendations, the creation of a network of population-based centers of excellence established through state public health departments collaborating with academic institutions, local health departments, public health and clinical laboratories, infection control professionals, healthcare providers, and CDC for special surveillance and applied public health research, which became the EIP network. The EIP network assists with local, state, and national efforts to prevent, control, and monitor the public health impact of infectious diseases. Activities of the EIP network fall into the following overall categories: (1) active infectious disease surveillance; (2) applied public health epidemiologic and laboratory activities; (3) implementation and evaluation of pilot prevention/intervention projects; and (4) rapid and flexible response to public health emergencies and newly emerging issues for infectious diseases. The EIP network is particularly suited to address key and emergent public health issues for the U.S. that require a collaborative approach across multiple sites and timely data to inform public health policy and practices and lead directly to the prevention of disease. The EIP network conducts active, population-based surveillance and special studies for respiratory viral diseases (influenza, COVID-19, RSV), invasive bacterial diseases including antibiotic-resistant infections, foodborne pathogens, healthcare-associated infections (HAIs), and many other infectious diseases. The COVID-19 pandemic has highlighted the importance of having a multi-center surveillance and applied research platform to rapidly respond to public health threats. The EIP network has also played a critical role in responding to emerging infectious diseases by rapidly implementing new collaborative activities, such as the establishment of COVID-NET to rapidly gather public health data for action on COVID-19 hospitalization rates, patient characteristics, and vaccine effectiveness.

## Questions people ask

### Is CDC-RFA-CK24-2401 still open?

No. It closed on June 20, 2023. A newer notice is forecast: CDC-RFA-CK-27-0046, expected deadline March 27, 2027.

### Who can apply for Emerging Infections Program?

Centers for Disease Control - NCEZID accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Emerging Infections Program?

Closed June 20, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $767 million in total across about 15 awards.

### Who has won Emerging Infections Programs grants before?

The largest recipients over five fiscal years were State of Georgia Department of Public Health, Minnesota Department of Health, Health Research, Inc. The program made 202 awards worth $514 million in that time.